
    
      The post market clinical investigation is designed to assess instrumented PLF using nanOss
      Bioactive 3D bone void filler with autograft bone and bone marrow aspirate in patients with
      symptomatic spinal stenosis secondary to degenerative disc disease (DDD) with up to Grade 1
      spondylolisthesis at one or two adjacent levels from L2-S1 characterized by the inclusion and
      exclusion criteria.

      Patients will be evaluated at Preop, discharge, 6 and 12 months. X-rays will be obtained at
      each visit; Additionally, a CT scan will be performed at the 12 month postoperative visit to
      assess fusion status.
    
  